|53.61||+3.31||+6.58%||Vol 202.62K||1Y Perf 177.78%|
|Apr 13th, 2021 15:38 DELAYED|
|- -%||- -|
|Target Price||87.14||Analyst Rating||Strong Buy 1.54|
|Potential %||62.76||Finscreener Ranking||★★★★★ 64.35|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 59.74|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 86.19|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||6.49B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||46.58||Earnings Date||6th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-0.35|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||333.05K|
|Avg. Monthly Volume||471.38K|
|Avg. Quarterly Volume||556.86K|
Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 50.3 per share at the end of the most recent trading day (a -3.27% change compared to the prior day closing price) with a volume of 548.87K shares and market capitalization of 6.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.
The one-year performance of Denali Therapeutics Inc. stock is 177.78%, while year-to-date (YTD) performance is -39.65%. DNLI stock has a five-year performance of %. Its 52-week range is between 18.45 and 93.94, which gives DNLI stock a 52-week price range ratio of 46.58%
Denali Therapeutics Inc. currently has a PE ratio of 84.10, a price-to-book (PB) ratio of 5.57, a price-to-sale (PS) ratio of 18.33, a price to cashflow ratio of 14.40, a PEG ratio of 2.32, a ROA of 6.45%, a ROC of -32.23% and a ROE of 9.00%. The company’s profit margin is 40.41%, its EBITDA margin is -980.80%, and its revenue ttm is $332.06 Million , which makes it $2.74 revenue per share.
Of the last four earnings reports from Denali Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.35 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.54), with a target price of $87.14, which is +62.76% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.56, ATR14 : 5.40, CCI20 : -123.64, Chaikin Money Flow : -0.14, MACD : -4.10, Money Flow Index : 32.52, ROC : -7.86, RSI : 38.00, STOCH (14,3) : 2.57, STOCH RSI : 0.10, UO : 28.15, Williams %R : -97.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $0), Alexander O. Schuth (Sold 104 515 shares of value $7 419 993 ), Carole Ho (Option Excercise at a value of $279 344), Carole Ho (Sold 71 135 shares of value $3 226 586 ), David P. Schenkein (Sold 80 000 shares of value $5 905 312 ), Douglas Bratton (Sold 3 935 726 shares of value $112 668 990 ), Douglas K. Bratton (Sold 6 152 524 shares of value $256 760 862 ), Marc Tessier-Lavigne (Sold 950 000 shares of value $30 333 277 ), Ryan J. Watts (Option Excercise at a value of $0), Ryan J. Watts (Sold 157 921 shares of value $11 174 031 ), Steve E. Krognes (Option Excercise at a value of $0), Steve E. Krognes (Sold 154 483 shares of value $10 243 441 ), Vicki L. Sato (Sold 3 332 shares of value $196 633 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.